Maintenance therapy after first-line chemoimmunotherapy for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study compares two maintenance treatments after initial chemotherapy plus immunotherapy for advanced esophageal squamous cell carcinoma. The goal is to see if adding anlotinib, a targeted drug that blocks blood vessel growth to tumors, to a PD-1 inhibitor is more effective than the PD-1 inhibitor alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of esophageal squamous cell carcinoma that is locally advanced, recurrent, or has spread, and you haven't had prior systemic treatment (unless recurrence was more than 6 months after finishing prior therapy).
- You have completed 4–6 cycles of PD-1 inhibitor combined with platinum-based chemotherapy and your cancer has not progressed.
- You are between 18 and 75 years old.
- Your overall health is good (ECOG score 0-1) and your doctor expects you to live more than 3 months.
- Your blood tests show adequate liver, kidney, and bone marrow function.
- You do not have severe heart conditions, uncontrolled high blood pressure, active infections, or significant bleeding or blood clot issues.
- You are not pregnant or breastfeeding and are willing to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
This trial tests a combination of immunotherapy and a drug called anlotinib (which helps stop blood vessel growth to tumors) after surgery for esophageal cancer. If you had some cancer left after surgery and it spread to lymph nodes, this treatment might help prevent the cancer from coming back.
This trial tests a new combination of two drugs, anlotinib and benmelstobart, for people with advanced esophageal squamous cell carcinoma that has not been treated before or has come back after more than six months. The goal is to see if this combination can help control the cancer and improve outcomes.
This trial is testing whether a maintenance therapy using anlotinib (a drug that blocks blood vessel growth) combined with immunotherapy can help keep extensive-stage small cell lung cancer from progressing after initial chemoimmunotherapy. It aims to see if this reduces the chance of the cancer coming back and improves survival.
This trial tests a combination of drugs (anlotinib, immunotherapy, and chemotherapy) given before surgery for esophageal cancer that has not spread to other organs. The goal is to see if this approach shrinks the tumor and improves outcomes.
Hear when a new Esophageal Cancer (EC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.